公开(公告)号：US20040106603A1

公开(公告)日：2004-06-03

申请号：US10657738

申请日：2003-09-08

申请人： Pfizer Inc

发明人： Jotham W. Coe ,  Christopher J. O'Donnell ,  Brian T. O'Neill ,  Lawrence A. Vincent

IPC分类号： A61K031/5513 ,  A61K031/506 ,  A61K031/501 ,  C07D487/04

CPC分类号： C07D487/08

摘要： The present invention relates to a compounds of formula I: 1 wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophrenia, depression, Alzheimer's disease, Parkinson's disease and ADHD. The present invention further comprises pharmaceutical compositions containing such compounds and methods of treatment comprising the use of such compounds.

摘要翻译： 本发明涉及式I化合物：其中A，B，D，E和F如本文所定义; 可用于治疗中枢神经系统（CNS）疾病，疾病和病症，例如但不限于尼古丁成瘾，精神分裂症，抑郁症，阿尔茨海默病，帕金森病和ADHD。 本发明还包含含有这些化合物的药物组合物和包括使用这些化合物的治疗方法。

公开(公告)号：US20020177591A1

公开(公告)日：2002-11-28

申请号：US10068692

申请日：2002-02-06

申请人： Pfizer Inc.

发明人： Christopher J. O'Donnell ,  Brian T. O'Neill

IPC分类号： A61K031/5513 ,  A61K031/498 ,  C07D487/04

CPC分类号： C07D213/30 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D471/08

摘要： The present invention relates to a method of treating disorders of the central nervous system (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant null7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant null7 nicotinic receptor agonist.

摘要翻译： 本发明涉及一种通过向哺乳动物施用CNS渗透剂α7烟碱受体激动剂来治疗哺乳动物（包括人）中的中枢神经系统（CNS）和其它疾病的疾病的方法。 它还涉及含有药学上可接受的载体和CNS渗透剂α7烟碱受体激动剂的药物组合物。

公开(公告)号：US20040204416A1

公开(公告)日：2004-10-14

申请号：US10833714

申请日：2004-04-27

申请人： Pfizer Inc

发明人： Brian Thomas O'Neill ,  Jotham Wadsworth Coe ,  Christopher J. O'Donnell

IPC分类号： A61K031/52 ,  A61K031/498 ,  A61K031/519

CPC分类号： C07D471/08

摘要： The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant null7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant null7 nicotinic receptor agonist.

公开(公告)号：US20030119837A1

公开(公告)日：2003-06-26

申请号：US10229447

申请日：2002-08-28

申请人： Pfizer Inc.

发明人： Brian Thomas O'Neill ,  Jotham Wadsworth Coe ,  Christopher J. O'Donnell

IPC分类号： A61K031/53 ,  A61K031/52 ,  A61K031/519 ,  C07D487/02 ,  C07D473/02

CPC分类号： C07D471/08

摘要： The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant null7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant null7 nicotinic receptor agonist.